Estrogen Decreases Expression of Chemokine Receptors, and Suppresses Chemokine Bioactivity in Murine Monocytes

Problem:  We propose that the ability of estrogen exposure to increase the probability of a woman developing breast cancer may be related to decreased chemokine activity and suppression of immune surveillance in mammary tissue. The present study was conducted to determine whether estrogen could decrease monocyte bioactivity through alteration of chemokine receptor expression.

[1]  M. Suematsu,et al.  Chronic inflammation upregulates chemokine receptors and induces neutrophil migration to monocyte chemoattractant protein-1. , 1999, The Journal of clinical investigation.

[2]  C. Schaniel,et al.  The Role of Chemokines in Regulating Cell Migration during Humoral Immune Responses , 1999, Cell.

[3]  J. S. Hunt,et al.  Sex steroid hormones and macrophage function. , 1996, Life sciences.

[4]  J. Demartino,et al.  Binding and Functional Properties of Recombinant and Endogenous CXCR3 Chemokine Receptors* , 1998, The Journal of Biological Chemistry.

[5]  M. Frazier-Jessen,et al.  Estrogen modulation of JE/monocyte chemoattractant protein-1 mRNA expression in murine macrophages. , 1995, Journal of immunology.

[6]  S. McColl,et al.  Chemokines: extracellular messengers for all occasions? , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[7]  C. Martínez-A,et al.  Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. , 1997, Journal of immunology.

[8]  S. Mizutani,et al.  Effects of 17β-estradiol and progesterone on migration of human monocytic THP-1 cells stimulated by minimally oxidized low-density lipoprotein in vitro , 1997 .

[9]  R. Frizzell,et al.  Taurodeoxycholate activates potassium and chloride conductances via an IP3-mediated release of calcium from intracellular stores in a colonic cell line (T84) , 1993, The Journal of clinical investigation.

[10]  J. Farber.  Mig and IP‐10: CXC chemokines that target lymphocytes , 1997, Journal of leukocyte biology.

[11]  J. Newcombe,et al.  Expression of the interferon‐γ‐inducible chemokines IP‐10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions , 2000, Neuropathology and applied neurobiology.

[12]  A. Mantovani,et al.  Single-cell analysis of macrophage chemotactic protein-1-regulated cytosolic Ca2+ increase in human adherent monocytes. , 1995, Blood.

[13]  R. Horuk,et al.  Chemokine Receptor Antagonists , 2000, Medicinal research reviews.

[14]  R. Holmdahl,et al.  Estrogen-mediated immunosuppression in autoimmune diseases , 1998, Inflammation Research.

[15]  C. Stewart,et al.  Cell preparation for the identification of leukocytes. , 1994, Methods in cell biology.

[16]  O. Quehenberger,et al.  Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. , 1999, Journal of lipid research.

[17]  D. Grainger,et al.  Tamoxifen: Teaching an old drug new tricks? , 1996, Nature Medicine.

[18]  B. Rollins,et al.  MCP‐1‐mediated chemotaxis requires activation of non‐overlapping signal transduction pathways , 1997, Journal of leukocyte biology.

[19]  H. Saji,et al.  Significant correlation of monocyte chemoattractant protein‐1 expression with neovascularization and progression of breast carcinoma , 2001, Cancer.

[20]  T. Paavonen,et al.  Hormonal regulation of immune responses. , 1994, Annals of medicine.

[21]  T. Bevers.  Raloxifene and the prevention of breast cancer , 2006, Expert opinion on pharmacotherapy.

[22]  J. Gaddy,et al.  Alloantigen-induced unresponsiveness in cord blood T lymphocytes is associated with defective activation of Ras. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Malling,et al.  CXC chemokine receptor 3 expression on CD34(+) hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: chemotaxis and adhesion induced by its ligands, interferon gamma-inducible protein 10 and monokine induced by interferon gamma. , 2000, Blood.

[24]  R. Santen,et al.  Three-component model of oestrogen formation and regulation of intratumoural oestrogen pool in breast neoplasms. , 1995, Medical hypotheses.

[25]  M. Baum.  Hormone replacement therapy and breast cancer , 1994, The Lancet.

[26]  K. Matsushima,et al.  Molecular analysis of the inhibition of monocyte chemoattractant protein-1 gene expression by estrogens and xenoestrogens in MCF-7 cells. , 2000, Endocrinology.

[27]  M. Rosenfeld,et al.  Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo : possible mechanisms for gender differences in atherosclerosis. , 1999, Circulation research.

[28]  A. Masi,et al.  Estrogens, the immune response and autoimmunity. , 1995, Clinical and experimental rheumatology.

[29]  H. Broxmeyer,et al.  In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. , 1998, Blood.

[30]  M. Frazier-Jessen,et al.  Estrogen regulation of JE/MCP‐1 mRNA expression in fibroblasts , 1996, Journal of leukocyte biology.

[31]  D. Taub,et al.  Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells , 1993, The Journal of experimental medicine.

[32]  M. Kuzuya,et al.  Physiological concentration of 17 beta-estradiol inhibits chemotaxis of human monocytes in response to monocyte chemotactic protein 1. , 1996, Artery.

[33]  F. Belardelli,et al.  Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: role of secreted MCP-1 in the regulation of the chemotactic response. , 1999, Blood.

[34]  K. Vaddi,et al.  Comparison of biological responses of human monocytes and THP‐1 cells to chemokines of the intercrine‐β family , 1994, Journal of leukocyte biology.

[35]  A. Wakeling,et al.  Similarities and distinctions in the mode of action of different classes of antioestrogens. , 2000, Endocrine-related cancer.

[36]  A. Mantovani,et al.  Receptor-activated calcium influx in human monocytes exposed to monocyte chemotactic protein-1 and related cytokines. , 1993, Journal of immunology.

[37]  G A Colditz,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[38]  G. Colditz,et al.  Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. , 1998, Journal of the National Cancer Institute.

[39]  D. Jarrossay,et al.  Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon , 1999, Nature Medicine.

[40]  K. Matsushima,et al.  Molecular Analysis of the Inhibition of Monocyte Chemoattractant Protein-1 Gene Expression by Estrogens and Xenoestrogens in MCF-7 Cells1. , 2000, Endocrinology.

[41]  M. Morrow,et al.  Tamoxifen, raloxifene, and the prevention of breast cancer. , 1999, Endocrine reviews.

[42]  B. Katzenellenbogen.  Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. , 1991, Journal of the National Cancer Institute.